Pharmacologic therapies after myocardial infarction

American Journal of Medicine

Volumn 101, Issue 4 A, 1996, Pages 61S-70S

  Rapaport, Elliot ^a   Gheorghiade, Mihai ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; DILTIAZEM; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; METOPROLOL; MORACIZINE; NIFEDIPINE; VERAPAMIL; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; RECURRENT DISEASE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; HUMANS; MYOCARDIAL INFARCTION; NITRATES; PLATELET AGGREGATION INHIBITORS; RECURRENCE; TREATMENT OUTCOME;

EID: 0029808663     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00322-1     Document Type: Conference Paper

References (61)

1. American Heart Association. Heart and Stroke Facts: Statistical Supplement. 1995, American Heart Association.
2. Pearson T, Rapaport E, Criqui M, et al. Optimal risk factor management in the patient after coronary revascularization: a statement for healthcare professionals from an American Heart Association Writing Group. Circulation. 1994;90:3125-3133.
3. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;8251:823-827.
4. The MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J. 1985;6:199-226.
5. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;i:57-66.
6. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
7. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714.
8. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27:335-371.
9. Kendall MJ, Lynch KP, Hjalmarson A, Kiekshus J. Beta blockers and sudden cardiac death. Ann Intern Med. 1995;123:358-367.
10. Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-510.
11. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422-437.
12. Karlson BW, Herlitz J, Hjalmarson Å. Impact of clinical trials on the use of beta blockers after acute myocardial infarction and its relation to other risk indicators for death and 1-year mortality rate. Clin Cardiol. 1994;17:311-316.
13. Vlay SC, Lawson WE. The safety of combined thrombolysis and beta adrenergic blockade in patients with acute myocardial infarction: A randomized study. Chest. 1988;93:716-721.
14. Pfeffer JM. Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibition. Am J Cardiol. 1991;68(suppl):17D-25D.
15. Warren SE, Royal HD, Markis JE, Grossman W, McKay RG. Time course of left ventricular dilation after myocardial infarction: Influence of infarct-related artery and success of coronary thrombolysis. "Boston Study." JAMA. 1988;11:12-19.
16. Hammermeister KE, DeRouen TA, Dodge HT. Effect of coronary surgery on survival in asymptomatic and minimally symptomatic patients. Circulation. 1980;62:198-1102.
17. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition Lancet. 1991;337:872-876.[Published erratum appears in Lancet 1991;337:1174.]
18. White HD. Remodelling of the heart after myocardial infarction. Aust NZ J Med. 1992;22:601-606.
19. Wollert KC, Studer R, von Bulow B, Drexler H. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation. 1994;90:2457-2467.
20. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
21. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation. 1994;90:1731-1738.
22. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
23. Kober L, Torp-Pederson C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
24. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-684.
25. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995;345:686-687.
26. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-685.
27. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol. 1996;27:337-344.
28. Ambrosioni E, Borghi C, Magnani B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:80-85.
29. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.[Published erratum appears in N Engl J Med 1992;327:1768.]
30. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
31. Cholesterol and Recurrent Events Study, Braunwald E. Presented at the American College of Cardiology 45th Annual Scientific Session; Orlando, Florida, March 26, 1996.
32. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;ii:349-360.
33. Almony GT, Lefkovits J, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol. 1996;93:357-365.
34. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.[Published erratum appears in BMJ 1994;308:1540.]
35. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509-1514.
36. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med. 1992;327:241-247.
37. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147-152.
38. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet. 1994;343:499-503.
39. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001.
40. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med. 1977;297:750-757.
41. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
42. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
43. Gheorghiade M, Goldstein S. Arrhythmia suppression in postmyocardial infarction patients with special notation to Cardiac Arrhythmia Suppression Trial. Prog Cardiovasc Dis. 1991;33:213-218.
44. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227-233.
45. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711-1718.
46. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind, placebo-controlled comparison. Circulation. 1984;69:740-747.
47. Simes PA, Overskeid K, Pedersen TR, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: Norwegian Nifedipine Multicenter Trial. Circulation. 1984;70:638-644.
48. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction. The TRENT study. BMJ 1986;293:1204-1208.
49. The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-364.
50. The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) II: Design, methods and results (abstract). Eur Heart J. 1988;9(suppl 1):350.
51. Report of the Holland Interuniversity Nifedpine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit. A randomized, double-blind placebo-controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J. 1986;56:400-414.
52. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-393.
53. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of double-blind, randomized, multicenter trial. N Engl J Med. 1986;315:423-429.
54. Reeves RA. Diltiazem in non-Q wave MI. (Letter) N Engl J Med. 1986;316:220-221.
55. Gibson RS, Young PM, Boden WE, Schechtman K, Roberts R, and the Diltiazem Reinfarction Study Group. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: Results from the multicenter Diltiazem Reinfarction Study. Am J Cardiol. 1987;60:203-209.
56. The Danish Study Group on Verapamil in Myocardial Infarction: Verapamil in acute myocardial infarction. Eur Heart J. 1984;5:516-528.
57. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarcton (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol. 1990;66:779-785.
58. Jugdutt BI, Warnsca JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: Effect of timing, dosage and infarct location. Circulation. 1988;78:906-911.
59. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
60. Clarkson TB, Hughes CL, Potrin Klein K. The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Prog Cardiovasc Dis. 1995;3:189-198.
61. Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ: Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136-1142.